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Leishmaniasis is a complex disease caused by parasitic protozoans which are transmitted to a susceptible host by 
phlebotomine sand ﬂies. Leishmania parasites cause leishmaniasis, with diverse epidemiological and clinical patterns. 
Owned dogs appeared to be a permanent, all seasons, source of infestation.  Depending on the conditions of the area, 
some areas such as Kruja (Albania) have ideal conditions for the presence of the vector and looked to be at a higher 
risk of exposure to phlebotomes. The relatively high number of owned dogs found positive for leishmaniasis, 
indicated that leishmaniasis should be taken seriously into consideration as a disease of zoonotic importance. Dog 
owners were usually willing to accept euthanasia as the first choice for their dogs. For the treatment of positive cases 
it were used melgumine antimoniate (glucantime), 100 mg/b.w., every day, s/c, for 20-30 days in a row and 
allopurinol 15 -20 mg/kg b.w., per os, twice daily for 30 days. Sometimes two drugs used usually combined together. 
In the case of treatment and recurrence are already cost and serious injuries to bring these preparations or their 
combined use in the liver and kidney. On the other hand, the study shows that Milteforan can be used with high 
efficiency against leishmaniasis at the dogs. Monitoring of haematological and biochemical indicators showed that the 
dog did not even care about the liver and kidneys. 
 
1. Introduction 
Leishmania is observed to be more common in dogs of western lowland and hilly areas (Ashford 
RW, 2000; Gramiccia M, and Gradoni L, 2007). In Albania the disease has a prevalence of 10% in 
non-endemic areas and about 15 % in endemic areas (Bizhga B, et al., 2013). Prevalence varies a 
lot considering the area, races and ages. According to the data collected from the Petlife Hospital 
in Tirana these prevalence’s are very different and are indicated from the age, sex, dogs breed, 
region etc. The setter dog checked in this hospital in the last 2 years resulted to have the highest 
seropositive for leishmaniasis in comparison with other races. Case brought in this study 
represents a dog which was presented in the hospital with a pathology which is accompanied also 
with epistaxis. Clinical status was evaluated according to criteria suggested by Abranches et al. 
1995. After clinical evaluation, dog resulted with two clinical signs of leishmaniasis (weight loss, 
dermatitis, hair loss, mouth and skin ulcers, enlarged lymph nodes, arthritis, and 
keratoconjuctivitis).  Considering its history, the area from which it came, hemorrhage and its 
possible cause trombocitopenia was suspected and diagnosed for leishmaniasis (Ashford RW, 
2000).  
Miltefosina per os is the actual solution for handling leishmaniasis in dogs diagnosed positive 
(Davidson RN, 1998). Each ml from the solution contains 20 mg miltefosine. Indication of the 
drug is medication of leishmaniasis in dogs (Baneth G, and Shaw SE, 2002).  Drug is administered 
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at a dose of 2 mg / kg weight, once daily for 28 days by mouth. Drug is well mixed in food or a 
part of it (Berman J, 2005). 
2. Material and Methods  
Animal  
Clinical case presented to the hospital on October 29, 2012. Dog breed Rottweiler, male sex, age 2 
years, weighted 40 kg, with good physical condition, was presented to the clinic because he had 
hemorrhagic leak from the nose. Were suspected for leishmaniasis and was undertaken relevant 
test which proved positive.  After rapid test animal was confirmed for positivity with ELISA 
technique with which even this technique resulted positive (Gramiccia M, and Gradoni L, 2007). 
The dog lives in the region of Kruja (Albania). The only thing that could have interest from 
history was that during one year he had external parasite (ticks and other). The client had not 
treated the dog before for the ectoparasites. Once the dog was diagnosed with visceral 
leishmaniasis was proposed to start the treatment with Milteforan for 29 days (Pearson RD, 2003). 
Indicators and time 
Before starting the treatment, we carried out haematological and biochemical analyzes in order to 
check the status of the blood elements HCT and PLT, and kidney and liver biochemical panels 
(Bianciardi  P, et al., 2009). 
The tests were done before Oct 29, 2012 and then we started the treatment with Milteforan 1ml/kg 
weight per os. We repeated the tests again on Nov 03, 2012. On 03/11/2012, 03/11/2012 again and 
tests were carried out after the date 01/12/2012. During the treatment of the dog (14-15 
treatments), there was not any health problem except one day in which the dog had a slight 
diarrhea. Also during the time of treatment, there were spontaneous leakage from the nose 
(bleeding) and in these case was used vitamin K.  
The Hematological and Biochemical values monitored for the treated dog. 
Blood was taken with EDTA and the monitoring was realized at Small Animal Hospital Petlife, in 
Tirana. Haematological examinations were carried out using the automatic Analyzer Sysmex. 
Biochemical indicators were studied in biochemical analyzer Cobra. Pet success during the 
examination of the blood parts realized the preparation directly to the animal, but also in the 
laboratory while following the asepsis rules.  
Microscopic examination identified changes in the blood picture and the presence of parasites. The 
microscopic evaluation of blood smear was conducted to identify the parameters of leukocyte 
formula. 
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3. Results and Discussion 
Table 1: Results of haematological examination on 31st October 2012 
 
a. The results of biochemical examination on 29th October, 2012.  
- Glucose 96 mg%  
- Urea 24.6  mg%  
- GOT   42 U l  
- GPT     20  U l  
- Creatinine 0,70  mg%  
In the dog was very evident anemia and thrombocytopenia. According to the recommendations 
from the drug manufacturers, milteforan had unsuccessful results when the hematocrit is below 
30%. In this case hematocrit resulted in 24.4. After consultation it was decided early treatment for 
2 reasons. First, the animal owner's insistence and second, considering the general condition of the 
animal. Treatment began on 1
st
 October 2012 with milteforan. The dose was 1 ml/10 kg body 
weight per os. During 29 days of treatment, the dog was treated with 4 ml per day which was 
thrown to him using a syringe in the mouth. Milteforan was exclusively from Virbac. While we 
perform full haemato-biochemical examination after two days from the start of the treatment. The 
reason was to follow the trend of haemato-biochemical examination (value of HCT) and the 
indicators of starting treatment. 
Table 2: The results of haematological examination on 3
rd
 November 2012 
Indicator Value Indicator Value 
E.O  3 710 000 MCV 62.8 
WBC 8 200 MCH 19.9 
Hct 23.3 MCHC 31 
Hgb 7,4 g/% Trombocites 156 000 
 
Animal medication started before 2 days and goes on to note the deepening of the state of anemia 
almost all indicators. Only the number of red blood cells remained constant whiles all the values 
of all indicators of the erythrocytes and hemoglobin is reduced. We examined that the level of 
hematocrit continues to fall. 
Indicator Value Indicator Value 
E.o.  3 370 000 MCV 63 
WBC 6 900 MCH 20.4 
Hct 24.4 MCHC 32.4 
Hgb 7,9 g/% Trombocites 156 000 
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b. The results of biochemical examination on 3rd November 2012.  
- Urea 19.5 mg% 
- GOT 74 U l 
- GPT 16  U l 
- Creatinine 0,71  mg% 
We repeated the full examination after two weeks since the begin of the treatment. In this time we 
expect the impact on the indicators of kidney function and liver. 
Table 3. The results of haematological examination on 17
th 
November 2012 
Indicator Value Indicator Value 
E.O 3 850 000 MCV 62.9 
WBC 10 200 MCH 20.6 
Hct 26.3 MCHC 30.8 
Hgb 8,0 g/% Trombocites 234 000 
In the beginning of the third week of treatment, there was a tendency of reduction of anemia in the 
entire indicators (Mateo M, et al., 2009.  
Clinically after 2 weeks since the begin of the treatment, the dog began to present problems with 
the gastrointestinal system, which consisted in the absence of appetite, nausea and vomiting and 




 day of the treatment. At the same time the treatment 
with Milteforan was continued and the clinical signs were stopped after symptomatic treatment 
(Miro´ G, et al., 2008).  
c. Biochemical examination on 17th November 2012.  
- Urea 59.5 mg%  
- GOT   84 U l  
- GPT     66 U l  
- Creatinine 0,85 mg%  
The last full examinations were conducted two days after the treatment finish. In this time we can 
see the last haemato-biochemical changes because the Milteforan can be used only after six 
months (Denerolle P, et al., 1999). 
Table 4: The results of haematological examination on 1
st
 December 2012, a day after the 
first session of treatment 
Indicator Value Indicator Value 
E.O 4 600 000 MCV 57.8 
WBC 12 100 MCH 20.4 
Hct 29.2 MCHC 31.5 
Hgb 9,0 g/% Trombocites 394 000 
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Monitoring on the first day after the end of the first session of treatment was observed the 
tendency of reduction of anemia in the entire indicators (Noli C, and Auxilia ST, 2005). We notice 
the highest number ever observed of leukocyte and the largest number of red blood cells which 




. (Verma NK, and Dey CS, 2004). 
These symptoms were interrupted after symptomatic treatment. However hematological indicators 
show that the situation was improving significantly on November 3
rd
. 
d. The results of biochemical examination on 1st December 2012.  
Urea 27.8 mg% 
GOT 66 U l 
GPT 20 U l 
Creatinine 0,97 mg% 
Despite that treatment has continued without interruption, and was discontinued only the first 2 
days we noticed a significant improvement compared with biochemical indicators on 17
th
 
November when they reached the peak and were observed also clinical signs related to the 
gastrointestinal tract (Pearson RD, 2003). 
The BUN level results are approximately 2 times lower compared to the peak founded on 17 
November (Costa F, et al., 2003). GOT levels decreased while the level of GPT results almost 3 
times lower than 17th November. Creatinine level had no insignificant variations along the 
treatment curve (Rodrigues ML, et al., 1999).. Clinical condition of the animal on 3
rd
 December 







Fig. 1. The dog before and after the treatment. 
The seropositive dog during almost every moment of laboratory examinations was evaluated and 
for the blood smears indicators. At the time of treatment, during the blood morphocytometric 
examination, was identified only increasing tendency of monocyte. At the same time, the 
leukocytosis resulted not evident. 
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4. Conclusions 
 Treatment with Milteforan results is highly effective for the treatment of dogs diagnosed 
seropositive for leishmaniasis.  
 Milteforan does not affect to the indicators of kidney and liver. 
 Milteforan could conceive of effective and following manufacturer’s criteria. Appreciating 
the side effects are almost negligible and this medicine can be used even when HCT is 
under 30 when the animal biological indicators enable its use. 
 Seropositivity leishmaniasis disease in dogs can be accomplished with rapid diagnostic 
kits. In most cases, ELISA confirms the effectiveness of rapid diagnostic Kitty. 
 Leukocytosis is not evident indication in sick animal with leishmaniasis.  
 Thrombocytopenia may serve as a key moment of the diagnosis of the disease, especially 
in case of the lack of disease clinic. The presence of blood monocytosis is very helpful in 
diagnosing the disease. 
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